Stay updated on ALN-TTRSC SubQ Clinical Trial
Sign up to get notified when there's something new on the ALN-TTRSC SubQ Clinical Trial page.

Latest updates to the ALN-TTRSC SubQ Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record now presents details of Alnylam’s completed Phase 1 revusiran study, including its design, eligibility criteria, study locations, and safety and pharmacology outcomes. It also includes the study’s record dates and investigator information.SummaryDifference36%

- Check19 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2. The study record content remains unavailable behind a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces updates to NIH websites and FAQs, including a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study details page now displays a 403 Forbidden error, replacing the previous content with an inaccessible state. This means the study information is temporarily unavailable to users.SummaryDifference0.5%

Stay in the know with updates to ALN-TTRSC SubQ Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALN-TTRSC SubQ Clinical Trial page.